Ozempic babies: fertility claims vs. what the data shows

What did @thebossticks actually say?

The video features a host and a doctor claiming that GLP-1 drugs like semaglutide are causing a wave of unplanned pregnancies, and that the mechanism runs through insulin regulation. The doctor says that once the insulin-glucose relationship is corrected, "your hormones actually can respond better, like all over your body, your thyroid, your reproductive hormones." She stops short of recommending GLP-1s as a direct fertility treatment, framing it more as an indirect benefit: use the drug to lose weight, and pregnancy rates may follow. She also hints that physicians may eventually deploy GLP-1s specifically to improve fertility outcomes in people with obesity.

The framing is casual and anecdote-forward. Phrases like "getting pregnant left and right" and "boom, getting pregnant" make this sound more like a fertility miracle than a plausible, evidence-supported physiological effect with a lot of asterisks still attached.

Does the science back this up?

Partially, yes, but the mechanism is more complicated than the video lets on. The insulin-fertility link is real, but it is most clearly established in people with polycystic ovary syndrome (PCOS), not in the general population of people with obesity.

PCOS affects roughly 10 percent of people with ovaries and is driven substantially by insulin resistance, which disrupts ovulation. Research published by Elkind-Hirsch et al. (2022, Journal of Clinical Endocrinology and Metabolism) found that GLP-1 receptor agonists improved menstrual regularity and reduced androgen levels in women with PCOS. A 2023 meta-analysis by Lim et al. in Obesity Reviews confirmed that GLP-1 agonists reduced testosterone and improved ovulation rates in PCOS patients specifically.

Weight loss itself also improves fertility. A long-standing body of evidence, including work by Norman et al. (2004, Human Reproduction), shows that even modest weight reduction of 5 to 10 percent body weight restores ovulation in a meaningful proportion of people with obesity-related anovulation. So the doctor is not wrong that weight loss helps. The question is whether GLP-1s are doing something extra beyond the weight loss itself, and that is genuinely unsettled.

What did they get wrong (or right)?

The doctor gets the basic PCOS-insulin story right. Insulin resistance drives androgen excess in PCOS, which suppresses ovulation, and correcting that relationship does improve reproductive hormone profiles. Credit where it is due.

But the claim that GLP-1s improve hormones "all over your body, your thyroid, your reproductive hormones" is too broad. Thyroid effects of GLP-1s are not an established clinical benefit in humans. Most thyroid findings from GLP-1 research relate to a rare risk of medullary thyroid carcinoma, not a beneficial thyroid-regulatory effect.

The "getting pregnant left and right" framing is also irresponsible without the context that semaglutide carries a pregnancy warning. Novo Nordisk explicitly recommends stopping Ozempic at least two months before a planned pregnancy because animal studies showed fetal harm at doses relevant to human exposure. There is no human safety data for GLP-1 use during pregnancy, and that omission in a 2 million-view video is a real problem.

The host's explanation that semaglutide "does something with your insulin" is vague enough to be technically defensible, but it flattens a nuanced mechanism into something that sounds almost magical.

What should you actually know?

If you have PCOS and insulin resistance, there is genuine emerging evidence that GLP-1 receptor agonists may improve ovulation and hormonal balance, and this is an active area of clinical research. This is not the same as saying GLP-1s are a fertility drug for everyone.

The most important thing this video did not say: if you are sexually active, not using contraception, and start a GLP-1 medication, you need to know that your contraceptive pill may be less effective in the first four weeks of semaglutide treatment due to delayed gastric emptying affecting oral medication absorption. The FDA label for Ozempic includes this warning. An unplanned pregnancy on semaglutide is not a cute TikTok moment. It is a clinical concern requiring immediate provider contact.

Anyone considering GLP-1 therapy who also wants to become pregnant should have that conversation explicitly with a physician before starting, not after noticing a missed period.

• GLP-1s are not approved as fertility treatments by the FDA.
• Stop semaglutide at least two months before attempting conception per manufacturer guidance.
• The fertility benefit is best established in people with PCOS and insulin resistance, not the general population.
• Oral contraceptive efficacy may be reduced during early GLP-1 treatment.